pmc logo image
Logo of aacAntimicrob Agents Chemother SubscriptionsAntimicrob Agents Chemother Web Site
Journal List > Antimicrob Agents Chemother > v.28(2); Aug 1985

Formats:
Antimicrob Agents Chemother. 1985 August; 28(2): 216–221.
PMCID: PMC180222
Copyright notice
Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults
F G Hayden,1,2† A Minocha,1 D A Spyker,1 and H E Hoffman3
Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville, Virginia 22908
2Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia 22908
Pharmaceuticals-Biomedical Products Department, E. I. DuPont de Nemours and Company, Newark, Delaware 19714
† Corresponding author
Small right arrow pointing to: This article has been corrected. See Antimicrob Agents Chemother. 1986 September; 30(3): 519.
 
Small right arrow pointing to: This article has been cited by other articles in PMC.
Abstract
The single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride were compared in a randomized, two-period, crossover study involving six young (less than or equal to 35 years) and six elderly (less than or equal to 60 years) adults. Subjects ingested single 200-mg oral doses after an overnight fast, and serial plasma (0 to 96 h), nasal mucus (0 to 8 h), and urine (0 to 24 h) samples were collected for assay of drug concentration by electron capture gas chromatography. For both groups combined, rimantadine differed significantly from amantadine in peak plasma concentration (mean +/- standard deviation, 0.25 +/- 0.06 versus 0.65 +/- 0.22 micrograms/ml), plasma elimination half-life (36.5 +/- 15 versus 16.7 +/- 7.7 h), and percentage of administered dose excreted unchanged in urine (0.6 +/- 0.8 versus 45.7 +/- 15.7%). No significant age-related differences were noted for rimantadine. Urinary excretion (0 to 24 h) of rimantadine and its hydroxylated metabolites averaged 19% of the administered dose. The maximum nasal mucus drug concentration was similar for both drugs (0.42 +/- 0.25 versus 0.45 +/- 0.32 micrograms/g), and the ratio of maximum nasal mucus to plasma concentration was over twofold higher after rimantadine than after amantadine. These findings may in part explain the clinical effectiveness of rimantadine in influenza A virus infections at dosages that have lower toxicity than those of amantadine.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 216
216
icon of scanned page 217
217
icon of scanned page 218
218
icon of scanned page 219
219
icon of scanned page 220
220
icon of scanned page 221
221
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther. 1985 Feb;37(2):137–144. [PubMed]
  • Aoki FY, Sitar DS, Ogilvie RI. Amantadine kinetics in healthy young subjects after long-term dosing. Clin Pharmacol Ther. 1979 Dec;26(6):729–736. [PubMed]
  • Aoki FY, Stiver HG, Sitar DS, Boudreault A, Ogilvie RI. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults. Clin Pharmacol Ther. 1985 Feb;37(2):128–136. [PubMed]
  • Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490. [PubMed]
  • Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982 Sep 2;307(10):580–584. [PubMed]
  • Fishaut M, Mostow SR. Amantadine for severe influenza A pneumonia in infancy. Am J Dis Child. 1980 Mar;134(3):321–323. [PubMed]
  • Hayden FG, Cote KM, Douglas RG., Jr Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980 May;17(5):865–870. [PubMed]
  • Hayden FG, Hoffman HE, Spyker DA. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother. 1983 Mar;23(3):458–464. [PubMed]
  • Horadam VW, Sharp JG, Smilack JD, McAnalley BH, Garriott JC, Stephens MK, Prati RC, Brater DC. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981 Apr;94(4 Pt 1):454–458. [PubMed]
  • Patriarca PA, Kater NA, Kendal AP, Bregman DJ, Smith JD, Sikes RK. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes. Antimicrob Agents Chemother. 1984 Jul;26(1):101–103. [PubMed]
  • Peck CC, Barrett BB. Nonlinear least-squares regression programs for microcomputers. J Pharmacokinet Biopharm. 1979 Oct;7(5):537–541. [PubMed]
  • Powell KR, Shorr R, Cherry JD, Hendley JO. Improved method for collection of nasal mucus. J Infect Dis. 1977 Jul;136(1):109–111. [PubMed]
  • Smith GB, Purcell RH, Chanock RM. Effect of amantadine hydrochloride on parainfluenza type 1 virus infections in adult volunteers. Am Rev Respir Dis. 1967 Apr;95(4):689–690. [PubMed]
  • Soung LS, Ing TS, Daugirdas JT, Wu MJ, Gandhi VC, Ivanovich PT, Hano JE, Viol GW. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med. 1980 Jul;93(1):46–49. [PubMed]
  • Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG., Jr Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981 Mar 20;245(11):1128–1131. [PubMed]
Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of
American Society for Microbiology (ASM)

PubMed articles by these authors